Medical Journal

Abstract Background Vulvovaginal candidiasis (VVC), caused primarily by Candida albicans , is treated with anti-fungal drugs, often with variable efficacy and relapses. New therapeutic strategies, including drug-free alternatives, are needed. Upon overgrowth or environmental triggers, C. albicans commensal yeast transitions into hyphae resulting in an aberrant immunopathologic neutrophil response that contributes to the characteristic signs and symptoms of vaginitis. The pur

To determine the effectiveness and speed of symptom relief of a vaginal cooling device (VCD) in the treatment of Vulvovaginal candidiasis (VVC). VVC causes itching, burning, pain or irritation, erythema, edema, excoriation and impacts quality of life, loss of confidence and self-esteem, and difficulties with sexual relations. Standard oral and local antifungal therapy have shortcomings including delayed symptomatic relief, increased drug resistance, decreased efficacy, side e